ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Inflammation Disrupts Memory - What Can You Do to Protect Your Brain?

All About Ginkgo Biloba: Benefits of This Timeless Herbal Supplement

Yarrow Oil: Here's Why It Deserves a Place in Your First-Aid Kit

Trial Finds Reduction in Depressive Symptoms Following Magnesium Supplementation

Artificial sweeteners linked to risk of weight gain, heart disease and other health issues

Carnitine deficiency suggested as contributor to autism

Vitamin D supplement use associated with lower risk of breast cancer

Hop Oil: A Safe Sleep Aide

White Camphor Oil: The Purest Camphor Oil

Lutein — An Important Nutrient for Eye and Brain Health

 
Print Page
Email Article

Novel Oral Drug for Rheumatoid Arthritis Completes Phase I Clinical Trial

  [ 9 votes ]   [ Discuss This Article ]
www.ProHealth.com • October 26, 2001




AGIX -4207, a novel oral agent being developed for the treatment of rheumatoid arthritis, has completed the escalating single-dose segment of its Phase I clinical trial. This is according to a recent announcement by the drugs manufacturer, AtheroGenics, Inc.

AGIX-4207 is a small molecule drug that represents a unique approach to treating rheumatoid arthritis. Unlike currently marketed biological TNF-alpha (tumor necrosis factor-alpha) inhibitors, AGIX-4207 is a selective modulator of TNF-alpha induced redox-sensitive inflammatory genes. By targeting a specific subset of TNF-alpha activity, it is believed that AGIX-4207 may decrease chronic inflammation in rheumatoid arthritis, while maintaining the body's ability to respond to infection.

The Phase I clinical trial is designed to study the safety, tolerability and pharmacokinetics of single and multiple doses of AGIX-4207 in healthy volunteers. A total of 48 patients in the single-dose segment of the Phase I trial received oral doses of AGIX-4207, ranging from 1mg to 150mg. AGIX-4207 was well tolerated by all patients, and there were no serious adverse events occurring in patients who received the drug. The data have been submitted to the U.S. Food and Drug Administration for review, and a multi-dose segment of the study is expected to be completed by the end of the year.

"We are delighted that AGIX-4207 has successfully completed this first stage of the trial, and we look forward to completing the multi-dosing before the end of this year," said AtheroGenics President and Chief Executive Officer, Russell Medford, M.D., Ph.D. "As we progress through these clinical trial milestones, we remain hopeful that AGIX-4207 might eventually provide those who suffer from rheumatoid arthritis with a safe and effective treatment option for their health and well being."

Rheumatoid arthritis is a chronic and progressively debilitating inflammatory disease that affects more than two million patients in the United States. Approximately 70 percent of those diagnosed with rheumatoid arthritis are young and middle-aged women. Physicians currently treat chronic rheumatoid arthritis in a stepwise fashion, escalating from a regimen of common anti-inflammatory agents like aspirin or ibuprofen, to the use of increasingly toxic drugs that may affect the body's immune system, such as DMARDs (Disease Modifying Anti-Rheumatic Drugs) or biological TNF-alpha inhibitors.



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Energy NADH™ 12.5mg Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Guarding Against the Dangers of Vitamin D Deficiency Guarding Against the Dangers of Vitamin D Deficiency
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
Three-Step Strategy to Reverse Mitochondrial Aging Three-Step Strategy to Reverse Mitochondrial Aging
The Genetic Mutation That May Compromise Your Health - And What to Do About It The Genetic Mutation That May Compromise Your Health - And What to Do About It
Natural Bladder Control, Go Less and Live More Natural Bladder Control, Go Less and Live More

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map